Table 2. Conjunctive Consolidation of Comorbidity and Age Into the FSSSa.
| Comorbidityb | Patient Age, yc | Total | ||||
|---|---|---|---|---|---|---|
| 18-39 | 40-49 | 50-59 | 60-69 | >69 | ||
| None | 137/137 (100) | 94/97 (97) | 56/56 (100) | 22/23 (96) | 12/15 (80)d | 321/328 (98) |
| Mild | 42/42 (100) | 42/43 (98) | 64/72 (89)d | 47/53 (89)d | 37/42 (88)d | 232/252 (92) |
| Moderate/severe | 18/19 (95) | 20/25 (80)c | 49/61 (80)d | 38/55 (69)e | 21/34 (62)e | 146/194 (75) |
| Total | 197/198 (99) | 156/165 (95) | 169/189 (89) | 107/131 (82) | 70/91 (77) | 699/774 (90) |
Abbreviations: ACE-27, Adult Comorbidity Evaluation-27; FSSS, functional severity staging system.
a
All data reported as number of patients alive at 5 years/total number of patients in the category (5-year survival rate as percentage).
b
Comorbidity was measured by the ACE-27 index.
c
Unless otherwise indicated, all data represent FSSS stage α disease.
d
FSSS stage β disease.
e
FSSS stage γ disease.